Stop Chinese Fentanyl Act of 2023
Why China-relevant: Title: 'Stop Chinese Fentanyl Act.' 'To impose sanctions with respect to Chinese producers of synthetic opioids and opioid precursors, to hold Chinese officials accountable...' Amends the Fentanyl Sanctions Act to include 'any entity of the People's Republic of China' and 'any senior official of the Government of the P
Path to becoming law
- Introduced
- Passed committee
- Passed House
- Passed Senate
- Sent to President
- Became law
done next step still ahead did not advance
Legislative timeline — dated actions so far
- Filed
- Advanced in committee
- Passed chamber (vote) [house]
Resolved. Model had estimated 4% to become law
- + Broad cosponsorship (10 cosponsors)
- + Sponsored by a member of the majority party
- + Bipartisan support (3/10 cosponsors from across the aisle)
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
Targets Chinese synthetic-opioid/precursor producers with sanctions, pressuring China-based chemical/API suppliers.
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |